Hrishikesh Kale

Hrishikesh Kale

Auto-generated profile, based on publicly available information

Hrishikesh Kale

Department of Risk Management and Epidemiology Purdue Pharma L.P. Stamford CT USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

30 September 2013 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Open access
PDF file
PCPaul M. Coplan
Paul M. Coplan
HKHrishikesh Kale
Hrishikesh Kale
LSLauren Sandstrom
Lauren Sandstrom
CLCraig Landau
Craig Landau
HCHoward D. Chilcoat
Howard D. Chilcoat
Purpose: Abuse and misuse of prescription opioids are serious public health problems. Abuse‐deterrent formulations are an intervention to balance risk mitigation with appropriate patient access. This study evaluated the effects of physicochemical barriers to crushing and dissolving on safety outcomes associated with extended‐release oxycodone (ERO) tablets (OxyContin) using a national surveillance system of poison centers. Other single‐entity (SE) oxycodone tablets and heroin were used as comparators and to assess substitution effects.Methods: The National Poison Data System covering all US poison centers was used to measure changes in exposures in the year before versus the 2 years after introduction of reformulated ERO (7/2009–6/2010 vs 9/2010–9/2012). Outcomes included abuse, therapeutic errors affecting patients, and accidental exposures.Results: After ERO reformulation, abuse exposures decreased 36% for ERO, increased 20% for other SE oxycodone, and increased 42% for heroin. Therapeutic errors affecting patients decreased 20% for ERO and increased 19% for other SE oxycodone. Accidental exposures decreased 39% for ERO, increased 21% for heroin, and remained unchanged for other SE oxycodone. During the study period, other interventions to reduce opioid abuse occurred, for example, educational and prescription monitoring programs. However, these have shown small effects and do not explain a drop for ERO exposures but not for other opioids.Conclusions: After ERO reformulation, calls to poison centers involving abuse, therapeutic errors affecting patients, and accidental exposures decreased for ERO, but not for comparator opioids. Abuse‐deterrent formulations of opioid analgesics can reduce abuse, but switching to other accessible non abuse‐deterrent opioids might occur. © 2013 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons, Ltd.

11 June 2014 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Open access
PDF file
NSNelson E. Sessler
Nelson E. Sessler
JDJerod M. Downing
Jerod M. Downing
HKHrishikesh Kale
Hrishikesh Kale
HCHoward D. Chilcoat
Howard D. Chilcoat
TBTodd F. Baumgartner
Todd F. Baumgartner
PCPaul M. Coplan
Paul M. Coplan
Purpose Abuse of opioid analgesics for their psychoactive effects is associated with a large number of fatalities. The effect of making opioid tablets harder to crush/dissolve on opioid-related fatalities has not been assessed. The objective of this study was to assess the impact of introducing extended-release oxycodone (ERO [OxyContin®]) tablets containing physicochemical barriers to crushing/dissolving (reformulated ERO) on deaths reported to the manufacturer. Methods All spontaneous adverse event reports of death in the US reported to the manufacturer between 3Q2009 and 3Q2013 involving ERO were used. The mean numbers of deaths/quarter in the 3 years after reformulated ERO introduction were compared with the year before. Changes in the slope of trends in deaths were assessed using spline regression. Comparison groups consisted of non-fatal reports involving ERO and fatality reports involving ER morphine. Results Reports of death decreased 82% (95% CI: −89, −73) from the year before to the third year after (131 to 23 deaths per year) reformulation; overdose death reports decreased 87% (95% CI: −93, −78) and overdose deaths with mention of abuse-related behavior decreased 86% (95% CI:−92, −75). In contrast, non-fatal ERO reports did not decrease post-reformulation, and reported ER morphine fatalities remained unchanged. The ratio of ERO fatalities to all oxycodone fatalities decreased from 21% to 8% in the year pre-reformulation to the second year post-reformulation. Conclusions These findings, when considered in the context of previously published studies using other surveillance systems, suggest that the abuse-deterrent characteristics of reformulated ERO have decreased the fatalities associated with its misuse/abuse. © 2014 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons, Ltd.

1 June 2019 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
HKHrishikesh P. Kale
Hrishikesh P. Kale
DMD'ARcy P. Mays
D'ARcy P. Mays
PNPramit A. Nadpara
Pramit A. Nadpara
PSPatricia W. Slattum
Patricia W. Slattum
APAsit K. Paul
Asit K. Paul
NCNorman V. Carroll
Norman V. Carroll

1 December 2018
Verified
Conference Paper
Closed access
HKHrishikesh Kale
Hrishikesh Kale
PMPrathamesh Mandke
Prathamesh Mandke
HMHrishikesh Mahajan
Hrishikesh Mahajan
VDVedant Deshpande
Vedant Deshpande
This paper proposes the use of artificial neural networks(ANNs) to classify human postures, using an invasive(intrusive) approach, into 6 categories namely standing, sitting, sleeping and bending - forward and backward. Human posture recognition has numerous applications in the field of healthcare analysis like patient monitoring, lifestyle analysis, elderly care etc. Most importantly, our solution is capable of classifying the aforementioned postures in real-time, by wirelessly(Wi-Fi) acquiring and processing the sensor data on a Raspberry-Pi device with minimal lag. A data-set of 44,800 samples was collected - from 3 subjects - which was used to train and test the neural network. After experimenting and testing with a plethora of network architectures, an optimal neural network architecture(6-9-6) with suitable hyper-parameters was determined which gave an overall accuracy of 97.589%.

30 September 2019 in Neuro-Oncology Practice
Verified
Journal Article
Closed access
AAAbdalla Aly
Abdalla Aly
PSPrianka Singh
Prianka Singh
BKBeata Korytowsky
Beata Korytowsky
YLYou-Li Ling
You-Li Ling
HKHrishikesh P Kale
Hrishikesh P Kale
ANAndrew D Norden
Andrew D Norden
Background: Glioblastoma (GBM) is associated with poor prognosis, large morbidity burden, and limited treatment options. This analysis evaluated real-world treatment patterns, overall survival, resource use, and costs among Medicare patients with GBM. Methods: This retrospective observational study evaluated Medicare patients age 66 years or older with newly diagnosed GBM using the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data from 2007 through 2013. Patients were followed from diagnosis to death or end of follow-up. An algorithm defined treatment patterns as lines of therapy (LOTs). The Kaplan-Meier method was used to estimate overall survival for the full sample as well as by LOT, surgical resection, Charlson Comorbidity Index (CCI), tumor size, and age. Resource use and costs during the follow-up period were reported in terms of total and per-patient-per-month (PPPM) estimates. Results: A total of 4308 patients with GBM were identified (median age, 74 years; CCI of 0, 52%). The most commonly used first LOT was temozolomide (82%), whereas chemotherapy + bevacizumab was most prevalent for second-line (42%) and third-line (58%) therapy. The median overall survival was 5.9 months for resected patients and 3 months for unresected patients, with considerable heterogeneity depending on patient characteristics. A great proportion of patients had claims for an ICU admission (86.2%), skilled nursing facility (76.9%), and home health (56.0%) in the postdiagnosis period. The cumulative mean cost was $95 377 per patient and $18 053 PPPM, mostly attributed to hospitalizations. Conclusions: Limited treatment options, poor survival, and economic burden emphasize the need for novel interventions to improve care for Medicare patients with GBM.